Publication at First Faculty of Medicine |
2013
Abstract
Targeted therapy with inhibitors of the vascular endothelial growth faktor (VEGF) pathway and mTOR inhibitors has become the cornerstone of systemic treatment of metastatic renal cell carcinoma (mRCC). In the hands of an experienced physician, the targeted therapy leads to significant improvement of prognosis and quality of life of patients with mRCC.